GM-CSF and low-dose araC treatment of AML in prolonged hypoplasia with residual leukemic cells after induction chemotherapy
Yonsei Medical Journal
;
: 91-96, 1994.
Artigo
em Inglês
| WPRIM
| ID: wpr-171806
ABSTRACT
We describe a case with acute myelogenous leukemia (AML; M2) who developed prolonged marrow hypoplasia with residual leukemic blasts and recurrent infections after induction chemotherapy. He was treated successfully with a sequential treatment of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and low-dose cytosine arabinoside (LD AraC). To the best of our knowledge this is the first reported case of a successful treatment of a patient with AML, who showed prolonged markedly hypocellular bone marrow with significant residual leukemic cells after induction chemotherapy, with a sequential treatment of GM-CSF and LD AraC.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Doenças da Medula Óssea
/
Leucemia Mieloide Aguda
/
Fator Estimulador de Colônias de Granulócitos e Macrófagos
/
Citarabina
/
Pessoa de Meia-Idade
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Yonsei Medical Journal
Ano de publicação:
1994
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS